Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 8/20 | 0.39 |
| ▸ | CTSL | P07711 | 5/20 | 0.39 |
| ▸ | CTSB | P07858 | 5/20 | 0.39 |
| ▸ | CTSS | P25774 | 3/20 | 0.39 |
| ▸ | CTSC | P53634 | 1/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14941327 | 0.80 | CHRM2 (0.35) | SLC18A3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL387110 | 0.79 | GPR119 (0.56) | GPR119CTSKCTSLCTSBCTSS | |
| SCHEMBL4380852 | 0.77 | MAOB (0.37) | SLC18A3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL27870587 | 0.77 | GPR119 (0.48) | GPR119CTSKCTSLCTSBCTSS | |
| SCHEMBL12367012 | 0.77 | SLC18A3 (0.37) | SLC18A3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL20851287 | 0.72 | SLC18A3 (0.37) | SLC18A3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL12284377 | 0.72 | SLC18A3 (0.37) | SLC18A3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL1098014 | 0.72 | NCF1 (0.48) | SLC18A3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL79852 | 0.72 | — | — | |
| SCHEMBL1543625 | 0.72 | CYP1A2 (0.38) | SLC18A3CHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107074838-B | Compound having GPR119 agonist activity, method for preparing the same, and pharmaceutical composition comprising the same as an effective ingredient | 东亚ST株式会社 | 2021-03-19 | — | — | CN | disclosed |
| EP-3212640-B1 | COMPOUND HAVING GPR119 AGONISTIC ACTIVITY, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AS EFFECTIVE COMPONENT | DONG A ST CO LTD (KR) | 2019-11-06 | — | — | EP | disclosed |
| EP-3212640-B1 | COMPOUND HAVING GPR119 AGONISTIC ACTIVITY, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AS EFFECTIVE COMPONENT | DONG A ST CO LTD (KR) | 2019-11-06 | — | — | EP | disclosed |
| US-10428055-B2 | Substituted piperidines having GPR119 agonistic activity | DONG-A ST CO., LTD. (KR) | 2019-10-01 | — | — | US | disclosed |
| US-10428055-B2 | Substituted piperidines having GPR119 agonistic activity | DONG-A ST CO., LTD. (KR) | 2019-10-01 | — | — | US | disclosed |
| US-20190092763-A1 | COMPOUND HAVING GPR119 AGONISTIC ACTIVITY, METHOD FOR PREPARING THE SAME, AND PHARMAECUTICAL COMPOSITION INCLUDING THE SAME AS EFFECTIVE COMPONENT | DONG-A ST CO., LTD. (KR) | 2019-03-28 | — | — | US | disclosed |
| US-20190092763-A1 | COMPOUND HAVING GPR119 AGONISTIC ACTIVITY, METHOD FOR PREPARING THE SAME, AND PHARMAECUTICAL COMPOSITION INCLUDING THE SAME AS EFFECTIVE COMPONENT | DONG-A ST CO., LTD. (KR) | 2019-03-28 | — | — | US | disclosed |
| EP-3212640-A1 | COMPOUND HAVING GPR119 AGONISTIC ACTIVITY, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AS EFFECTIVE COMPONENT | Dong-A ST Co., Ltd. (KR) | 2017-09-06 | — | — | EP | disclosed |
| WO-2016068453-A1 | COMPOUND HAVING GPR119 AGONISTIC ACTIVITY, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AS EFFECTIVE COMPONENT | DONG-A ST CO., LTD. (KR) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016068453-A1 | COMPOUND HAVING GPR119 AGONISTIC ACTIVITY, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AS EFFECTIVE COMPONENT | DONG-A ST CO., LTD. (KR) | 2016-05-06 | — | — | WO | disclosed |
| WO-2009105717-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009105717-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009038974-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009034388-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2009-03-19 | — | — | WO | disclosed |
| WO-2008097428-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008081207-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008081206-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008081208-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008081204-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008081205-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428055-B2 | Substituted piperidines having GPR119 agonistic activity | GPR119, GPR84, GPR88 | GPR119 1/4885CTSK 1681/4885CTSL 2631/4885 |
| US-20190092763-A1 | COMPOUND HAVING GPR119 AGONISTIC ACTIVITY, METHOD FOR PREPARING THE SAME, AND PHARMAECUTICAL COMPOSITION INCLUDING THE SAME AS EFFECTIVE COMPONENT | GPR119, FFAR2, GCGR | GPR119 1/4885CTSK 2052/4885CTSL 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.